Influenza is an acute respiratory infection caused by influenza viruses leading to illness that affects humans and animals. These viruses are genetically dynamic and evolve unpredictively each year on seasonal basis. Thus, seasonal influenza epidemics are caused by newer strains that are antigenically different from the previous circulating strains. The changes in the genetics of the influenza virus strains further results in the development of new vaccines yearly.

Request for Sample Report@ https://www.alliedmarketresearch.com/request-sample/1437

Factors that boost the growth of the influenza vaccine market include increase in government support and surveillance regarding vaccination against influenza on the national and global levels to monitor the supply, distribution, and administration of flu vaccines. Moreover, rise in investment by leading market players across the globe and surge in government funding which has facilitated the launch of therapeutically effective vaccines drive the market growth.

COVID-19 Impact Analysis:
The COVID-19 outbreak is anticipated to have a positive impact on growth of the global influenza vaccine market. The COVID-19 pandemic has stressed the healthcare systems in the world. The number of populations effected with COVID-19 virus increases, surge the demand for influenza vaccine. The influenza vaccine will not prevent COVID-19, but will decrease the illness, death and hospitalization. According to European Congress of Clinical Microbiology & infectious diseases (ECCMID), in 2021, it was reported that around 75,000 COVID-19 patients having shot of influenza vaccine are less prone to sepsis, stroke and deep vein thrombosis. As per the same source, in 2021, it was observed that flu vaccine may offer protection against COVID-19 virus. The patient suffering from COVID-19, and vaccinated with influenza vaccine are also less likely to admitted in intensive care unit. Subsequently, this leads to increase in demand for influenza vaccine.

North America was the highest revenue contributor in the global influenza vaccine market and accounted for a 47.80% share in 2020. On the other hand, Middle East and Africa is expected to grow at a CAGR of 8.0%, owing to rise in incidences of influenza among children and increase in disposable income.

Some of the key players operating in the influenza vaccine market are AstraZeneca plc., Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., GlaxoSmithKline plc, Merck & Co. Inc. (Merck Sharp & Dohme Corp.), Novartis AG, Pfizer, Inc., Sanofi Pasteur SA, and Sinovac Biotech Ltd.

Key Findings of the Reports:
• By vaccine type, quadrivalent segment accounted for nearly 63% share of the Influenza Vaccine market in 2020.
• By technology, the egg-based segment expected to grow at a CAGR of 7.70% from 2021 to 2030.
• By age group, the adult segment held largest market share in of 61% in 2020 and is expected to remain dominant throughout the forecast period.
• By route of administration, the injection segment expected to grow at a CAGR of 7.40% from 2021 to 2030.
• By region, North America is expected to provide lucrative market growth opportunities and grow at a CAGR of 6.9% from 2021 to 2030.